OA08952A - Anticorps monoclonal anti-idiotypique, fragments Fv, Fab, Fab', et F(ab')2 de cet anticorps monoclonal, procédé pour produire l'anticorps monoclonal, et procédé pour contrôler les niveaux de l'anticorps anti-idiotypique dans les sérums - Google Patents

Anticorps monoclonal anti-idiotypique, fragments Fv, Fab, Fab', et F(ab')2 de cet anticorps monoclonal, procédé pour produire l'anticorps monoclonal, et procédé pour contrôler les niveaux de l'anticorps anti-idiotypique dans les sérums

Info

Publication number: OA08952A
Authority: OA; OAPI
Prior art keywords: tumor; antibody; monoclonal antibody; idiotypic; fab
Prior art date: 1987-09-10

Application number

OA59429A

Other languages

English (en)

French (fr)

Original Assignee

Oncogen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-10

Filing date

1988-09-09

Publication date

1990-11-30

1987-11-04 Priority claimed from US07/116,802 external-priority patent/US4918164A/en

1988-09-09 Application filed by Oncogen filed Critical Oncogen

1990-11-30 Publication of OA08952A publication Critical patent/OA08952A/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5757—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofoetal proteins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

OA59429A 1987-09-10 1988-09-09 Anticorps monoclonal anti-idiotypique, fragments Fv, Fab, Fab', et F(ab')2 de cet anticorps monoclonal, procédé pour produire l'anticorps monoclonal, et procédé pour contrôler les niveaux de l'anticorps anti-idiotypique dans les sérums OA08952A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US9609587A	1987-09-10	1987-09-10
US07/116,802 US4918164A (en)	1987-09-10	1987-11-04	Tumor immunotherapy using anti-idiotypic antibodies
US07/225,446 US5614610A (en)	1984-12-21	1988-07-28	Tumor immunotherapy using anti-idiotypic antibodies

Publications (1)

Publication Number	Publication Date
OA08952A true OA08952A (fr)	1990-11-30

Family

ID=27378089

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA59429A OA08952A (fr)	1987-09-10	1988-09-09	Anticorps monoclonal anti-idiotypique, fragments Fv, Fab, Fab', et F(ab')2 de cet anticorps monoclonal, procédé pour produire l'anticorps monoclonal, et procédé pour contrôler les niveaux de l'anticorps anti-idiotypique dans les sérums

Country Status (16)

Country	Link
US (1)	US5614610A (ja)
EP (2)	EP0306995B1 (ja)
JP (1)	JPH02494A (ja)
AT (1)	ATE151079T1 (ja)
AU (1)	AU630592B2 (ja)
DE (1)	DE3855850T2 (ja)
DK (1)	DK500888A (ja)
ES (1)	ES2102978T3 (ja)
FI (1)	FI884114L (ja)
GR (1)	GR3023725T3 (ja)
HU (1)	HU206394B (ja)
IL (1)	IL87692A (ja)
NO (1)	NO178464C (ja)
NZ (1)	NZ226129A (ja)
OA (1)	OA08952A (ja)
PT (1)	PT88459B (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS60255209A (ja) *	1984-05-30	1985-12-16	Mitsubishi Heavy Ind Ltd	圧延機におけるエツジヤ開度制御方法
AU607533B2 (en) *	1987-08-07	1991-03-07	Xoma Corporation	Methods and compositions for mimicking antigenic determinants
US6432402B1 (en)	1989-05-25	2002-08-13	Sloan-Kettering Institute For Cancer Research	Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
EP1334984A1 (en) *	1989-05-25	2003-08-13	Sloan-Kettering Institute For Cancer Research	Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
US6805862B1 (en)	1989-05-25	2004-10-19	Sloan-Kattering Institute For Cancer Research	Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
ATE184704T1 (de) *	1989-11-03	1999-10-15	Donald L Morton	Nachweismethode für harnkarzinom-assoziierte antigene
JPH04148298A (ja) *	1990-10-08	1992-05-21	Matsushita Electric Ind Co Ltd	違法駐車検出警告装置
DE4208795A1 (de) *	1992-03-19	1993-09-23	Behringwerke Ag	Monoklonaler anti-gangliosid-antikoerper, seine herstellung und verwendung als tumortherapeutikum
SE470285B (sv) *	1992-05-22	1994-01-10	Volvo Penta Ab	Drivaggregat för fartyg
US5861158A (en) *	1993-11-17	1999-01-19	The United States Of America As Represented By The Deptartment Of Health And Human Services	Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
US5798100A (en) *	1994-07-06	1998-08-25	Immunomedics, Inc.	Multi-stage cascade boosting vaccine
US7354587B1 (en) *	1994-07-06	2008-04-08	Immunomedics, Inc.	Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
AU5909900A (en) *	1999-07-02	2001-01-22	Life Time Pharmaceuticals, Inc.	Predicting immunotherapy effectiveness through delayed type hypersensitivity
EP1221961A4 (en) *	1999-10-13	2004-03-31	Roswell Park Memorial Inst	INDUCTION OF A STRONG IMMUNE RESPONSE TO A TUMOR-RELATED SELF-ANTIGEN
CA2515779A1 (en)	2003-02-14	2004-09-02	The Curators Of The University Of Missouri	Contraceptive method and compositions related to proteasomal interference
AT500650B1 (de) *	2003-04-17	2009-11-15	Altropus Gmbh	Immunogener rekombinanter antikörper
DE10352977A1 (de) *	2003-11-13	2005-06-09	Müller-Hermelink, Hans Konrad, Prof. Dr.	Muriner anti Idiotyp-Antikörpers oder anti Idiotyp-Antikörper aus der Ratte des humanen monoklonalen SC-1 Antikörpers
US8652484B2 (en)	2004-02-13	2014-02-18	Immunomedics, Inc.	Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US9481878B2 (en)	2004-02-13	2016-11-01	Immunomedics, Inc.	Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110020273A1 (en) *	2005-04-06	2011-01-27	Ibc Pharmaceuticals, Inc.	Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US20110064754A1 (en) *	2005-03-03	2011-03-17	Center For Molecular Medicine And Immunology	Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US8491914B2 (en) *	2004-02-13	2013-07-23	Ibc Pharmaceuticals, Inc.	Dock-and-lock (DNL) complexes for delivery of interference RNA
US8551480B2 (en)	2004-02-13	2013-10-08	Immunomedics, Inc.	Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8435539B2 (en) *	2004-02-13	2013-05-07	Immunomedics, Inc.	Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8562988B2 (en) *	2005-10-19	2013-10-22	Ibc Pharmaceuticals, Inc.	Strategies for improved cancer vaccines
JP4929864B2 (ja)	2006-06-15	2012-05-09	株式会社デンソー	配管継手装置
CN102186499B (zh) *	2008-08-20	2015-05-20	Ibc医药公司	用于癌症治疗的对接和锁定(dnl)疫苗
AU2011295968B2 (en) *	2010-09-01	2017-01-05	Biogen Ma Inc.	Rapid generation of anti-idiotypic antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0720884B2 (ja) *	1983-11-07	1995-03-08	ザ・ウイスタ−・インスティテュ−ト	抗イデイオタイプ抗体によって誘発される、腫瘍およびウイルスに対する免疫応答
JPS60155133A (ja) *	1983-11-09	1985-08-15	シンビオテイツクス　コ−ポレイシヨン	アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン
US4699880A (en) *	1984-09-25	1987-10-13	Immunomedics, Inc.	Method of producing monoclonal anti-idiotype antibody
US4906562A (en) *	1984-12-21	1990-03-06	Oncogen	Monocolonal antibodies and antigen for human non-small cell lung carcinomas
US4918164A (en) *	1987-09-10	1990-04-17	Oncogen	Tumor immunotherapy using anti-idiotypic antibodies

1988
- 1988-07-28 US US07/225,446 patent/US5614610A/en not_active Expired - Fee Related
- 1988-09-07 FI FI884114A patent/FI884114L/fi not_active Application Discontinuation
- 1988-09-07 IL IL8769288A patent/IL87692A/en not_active IP Right Cessation
- 1988-09-08 PT PT88459A patent/PT88459B/pt not_active IP Right Cessation
- 1988-09-09 NO NO884024A patent/NO178464C/no unknown
- 1988-09-09 AU AU22077/88A patent/AU630592B2/en not_active Ceased
- 1988-09-09 HU HU884647A patent/HU206394B/hu not_active IP Right Cessation
- 1988-09-09 DE DE3855850T patent/DE3855850T2/de not_active Expired - Fee Related
- 1988-09-09 EP EP88114834A patent/EP0306995B1/en not_active Expired - Lifetime
- 1988-09-09 AT AT88114834T patent/ATE151079T1/de active
- 1988-09-09 DK DK500888A patent/DK500888A/da not_active Application Discontinuation
- 1988-09-09 OA OA59429A patent/OA08952A/xx unknown
- 1988-09-09 JP JP63224877A patent/JPH02494A/ja active Pending
- 1988-09-09 EP EP96111623A patent/EP0759442A1/en not_active Withdrawn
- 1988-09-09 ES ES88114834T patent/ES2102978T3/es not_active Expired - Lifetime
- 1988-09-12 NZ NZ226129A patent/NZ226129A/en unknown
1997
- 1997-06-11 GR GR970401369T patent/GR3023725T3/el unknown

Also Published As

Publication number	Publication date
EP0759442A1 (en)	1997-02-26
NO178464C (no)	1996-04-03
JPH02494A (ja)	1990-01-05
AU2207788A (en)	1989-03-16
DE3855850D1 (de)	1997-05-07
EP0306995A3 (en)	1990-03-07
AU630592B2 (en)	1992-11-05
FI884114A0 (fi)	1988-09-07
NO884024D0 (no)	1988-09-09
DE3855850T2 (de)	1997-11-20
ATE151079T1 (de)	1997-04-15
EP0306995B1 (en)	1997-04-02
FI884114A7 (fi)	1989-03-11
EP0306995A2 (en)	1989-03-15
US5614610A (en)	1997-03-25
HUT47973A (en)	1989-04-28
PT88459B (pt)	1993-01-29
DK500888D0 (da)	1988-09-09
GR3023725T3 (en)	1997-09-30
HU206394B (en)	1992-10-28
NO178464B (no)	1995-12-27
DK500888A (da)	1989-03-11
NO884024L (no)	1989-03-13
ES2102978T3 (es)	1997-08-16
FI884114L (fi)	1989-03-11
IL87692A (en)	1994-04-12
NZ226129A (en)	1991-12-23

Publication	Publication Date	Title
OA08952A (fr)	1990-11-30	Anticorps monoclonal anti-idiotypique, fragments Fv, Fab, Fab', et F(ab')2 de cet anticorps monoclonal, procédé pour produire l'anticorps monoclonal, et procédé pour contrôler les niveaux de l'anticorps anti-idiotypique dans les sérums
EP0141783B2 (en)	1993-06-16	Immune response to tumours and viruses induced by anti-idiotype antibodies
Hough et al.	1976	Anti-idiotype sera raised against surface immunoglobulin of human neoplastic lymphocytes.
DK0626390T3 (da)	2002-03-11	Humaniserede antistoffer
MX9701859A (es)	1998-07-31	Anticuerpos monoclonales en contra de antigenos asociados con carcinoma de colon humano, y usos de los mismos.
IL74156A (en)	1990-08-31	Method for the preparation of a monoclonal antibody and of an immortalized cell producing the same and pharmaceutical compositions containing the monoclonal antibody
Hála et al.	1986	A monoclonal antibody reacting with a membrane determinant expressed on activated chicken T lymphocytes
EP0678744A3 (en)	1995-12-13	Detection method for urinary carcinoma-associated antigens.
AU629135B2 (en)	1992-09-24	Monoclonal antibody against melanoma
DK185086D0 (da)	1986-04-22	Tumor-associeret antigen, antistoffer specifikke herfor samt fremgangsmaade til disses fremstilling
DE69633976D1 (de)	2005-01-05	Monoklonale antikörper und antigene mit bezug zum menschlichen lungenadenokarzinom und immunoassay-verfahren unter verwendung desselben
US4661446A (en)	1987-04-28	Monoclonal antibodies and method of immunizing therewith
HUT48679A (en)	1989-06-28	Process for producing monoclonal antibodies recognizing alpha 2--->3 bonds
ZA884777B (en)	1990-03-28	Antigen recognized by mca 16 88
FR2571146B1 (fr)	1988-02-26	Antigenes carcino-foetaux du pancreas humain et un procede de purification, antiserum contre ces antigenes et son procede de preparation et compositions diagnostiques les contenant
EP0040020A3 (en)	1982-01-13	Human reverse transcriptase enzyme, method for its purification, and its use in the detection of breast cancer
JPS6471483A (en)	1989-03-16	Monoclonal antibody for immunological detection of phytophthora and hybridoma producing said antibody
Kearney et al.	1982	CRP-associated determinant expressed by human monocytes
AU7145087A (en)	1988-10-13	Tumor-associated antigens (mol wt 160,000-170,000; 44,000-46,000; 29,000-35,000)
Velge-Roussel et al.	1991	Functional analysis of a T cell line specific for antiidiotypic antibodies to a Schistosoma mansoni protective epitope. I. Role in the anti-S. mansoni antibody response
BE899484A (fr)	1984-10-22	Nouveaux determinants antigeniques apparentes a l'adenocarcinome et anticorps qui leur sont specifiques.
ES2151646T3 (es)	2001-01-01	Procedimiento para la identificacion o dosificacion inmunologica de antigenos polipeptidicos.
IT1254570B (it)	1995-09-25	Antigeni legati alla superfice esterna di eritrociti e procedimento per la loro preparazione.